[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "(484) 254-6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 66, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 630198, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard Clavano Narido", "age": 45, "title": "CFO & Treasurer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 255015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 62, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 76, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 60, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.19, "open": 1.17, "dayLow": 1.17, "dayHigh": 1.22, "regularMarketPreviousClose": 1.19, "regularMarketOpen": 1.17, "regularMarketDayLow": 1.17, "regularMarketDayHigh": 1.22, "beta": 1.271, "forwardPE": -40.666668, "volume": 73489, "regularMarketVolume": 73489, "averageVolume": 143552, "averageVolume10days": 197560, "averageDailyVolume10Day": 197560, "bid": 1.17, "ask": 1.24, "bidSize": 100, "askSize": 100, "marketCap": 14754802, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 7.33, "fiftyDayAverage": 1.3351, "twoHundredDayAverage": 2.71832, "currency": "USD", "enterpriseValue": 18638352, "floatShares": 7939651, "sharesOutstanding": 12094100, "sharesShort": 682658, "sharesShortPriorMonth": 532088, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0635, "heldPercentInsiders": 0.23562, "heldPercentInstitutions": 0.060500003, "shortRatio": 4.8, "shortPercentOfFloat": 0.0769, "impliedSharesOutstanding": 12094100, "bookValue": -1.419, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -24828000, "trailingEps": -2.11, "forwardEps": -1.27, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToEbitda": -0.801, "52WeekChange": -0.6393939, "SandP52WeekChange": 0.31426477, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NRXP", "underlyingSymbol": "NRXP", "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1512397800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e9e53629-f0c1-3f0f-8011-e7d950c4534d", "messageBoardId": "finmb_319388181", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.22, "targetHighPrice": 45.0, "targetLowPrice": 19.0, "targetMeanPrice": 31.66667, "targetMedianPrice": 31.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 1898000, "totalCashPerShare": 0.175, "ebitda": -23257000, "totalDebt": 7651000, "quickRatio": 0.08, "currentRatio": 0.206, "returnOnAssets": -1.15971, "freeCashflow": -7350500, "operatingCashflow": -13989000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-07"}]